Anzeige
Mehr »
Login
Freitag, 25.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40HU3 | ISIN: US3207033099 | Ticker-Symbol:
NASDAQ
24.04.25
21:49 Uhr
0,480 US-Dollar
+0,006
+1,24 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CALIDI BIOTHERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
CALIDI BIOTHERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur CALIDI BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiCalidi Biotherapeutics appoints new CEO2
MiCalidi Biotherapeutics names Poma as CEO4
MiCalidi Biotherapeutics, Inc. - 8-K, Current Report1
MoUS FDA clears Calidi's CLD-201 for clinical development in solid tumours1
10.04.Calidi Biotherapeutics Names Guy Travis Clifton Chief Medical Officer1
10.04.Calidi Biotherapeutics, Inc. - 8-K, Current Report-
31.03.Calidi Biotherapeutics, Inc. - 8-K, Current Report2
31.03.Calidi Biotherapeutics, Inc. - 10-K, Annual Report2
CALIDI BIOTHERAPEUTICS Aktie jetzt für 0€ handeln
31.03.Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement1
31.03.Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights59Announced demonstrated ability to deliver transient gene therapy (payload) to tumors using systemic antitumor virotherapy platform Filed IND in March 2025 for CLD-201 company sponsored Phase 1 trial...
► Artikel lesen
28.03.Calidi Biotherapeutics sinks after pricing $3.9M registered direct offering4
28.03.Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement1
14.03.RedChip Companies, Inc.: Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV269ORLANDO, FL / ACCESS Newswire / March 14, 2025 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and Calidi Biotherapeutics, Inc. (NYSE American:CLDI) on the RedChip...
► Artikel lesen
10.03.Calidi Biotherapeutics, Inc. - 8-K, Current Report2
10.03.Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform139SAN DIEGO, March 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
► Artikel lesen
28.02.Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV340ORLANDO, FLORIDA / ACCESS Newswire / February 28, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and OS Therapies Inc. (NYSE American:OSTX) on the...
► Artikel lesen
24.02.Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital86SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
► Artikel lesen
29.01.Calidi Biotherapeutics, Inc: Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 52
28.01.Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement2
28.01.Calidi Biotherapeutics, Inc. - 8-K, Current Report-
Seite:  Weiter >>
50 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1